VOYAGER THERAPEUTICS INC (VYGR)
Sector: Health Care
2026 Annual Meeting Analysis
VOYAGER THERAPEUTICS INC · Meeting: June 9, 2026
Directors FOR
0
Directors AGAINST
3
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Against Analysis
The 3-year underperformance trigger fires (VYGR trailed the peer group median by 34.5 percentage points over three years, exceeding the 20-point threshold), but the 5-year check shows VYGR actually outperformed the peer median by 52 percentage points over five years, indicating the recent underperformance is a short-term trough rather than sustained value destruction, so the vote is upgraded to FOR.
The 3-year underperformance trigger fires for Dr. Hyman (director since 2015, full tenure overlap), but the 5-year TSR check shows Voyager outperformed peers over the longer window, suggesting the recent three-year decline is a transient setback within an otherwise adequate long-term record, so the vote is upgraded to FOR.
For Analysis
All three Class II director nominees — Geraghty (director since 2014), Hyman (director since 2015), and Sandrock (director/CEO since 2022) — trip the 3-year TSR underperformance trigger under the named peer group benchmark (VYGR trailed peers by 34.5 percentage points over three years, exceeding the 20-point threshold for companies with negative absolute TSR). However, the 5-year supplementary check shows Voyager outperformed its peer median by 52 percentage points over five years, which under policy means the 3-year underperformance appears to be a recent trough within a longer track record of adequate performance. Policy directs a downgrade from AGAINST to FOR for all three nominees. Votes FOR all three nominees.
Say on Pay
✓ FORCEO
Alfred Sandrock, M.D., Ph.D.
Total Comp
$2,508,370
Prior Support
94.9%%
The CEO's total compensation of $2,508,370 is reasonable for a biotech company of Voyager's size and stage, with a mix of base salary ($674,903), performance-based cash bonus ($361,917), restricted stock units, stock options, and performance stock awards tied to clinical milestones — the majority of pay is variable and equity-linked, satisfying the 50-60% variable pay requirement. The prior year say-on-pay vote received 94.9% support, well above the 70% threshold, indicating strong shareholder alignment. The company has a meaningful clawback policy in place compliant with Nasdaq and Dodd-Frank requirements, and the compensation structure does not trigger any individual or aggregate benchmarking flags that would warrant a NO vote.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
The proxy does not disclose auditor tenure or the fee table needed to calculate the non-audit fee ratio; per policy, the tenure trigger requires confirmed data to fire and the fee ratio trigger requires disclosed fee data, so neither trigger applies, and the default vote is FOR. Ernst & Young is a Big 4 firm appropriate for a company of Voyager's size and complexity.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 4
Approval of Amendment to Fifth Amended and Restated Certificate of Incorporation to Increase Authorized Shares of Common Stock from 120,000,000 to 240,000,000 shares
This is a board-proposed charter amendment to double the authorized common stock from 120 million to 240 million shares. For a small-cap biotech company like Voyager with a $225 million market cap that relies on equity financings to fund its R&D pipeline, maintaining adequate authorized share capacity is a legitimate operational need — without sufficient authorized shares, the company could be unable to raise capital or issue equity to attract employees. The proposal does not appear designed to entrench management or impede shareholder rights, and increasing authorized shares is a standard and routine housekeeping measure for companies at this stage, making a FOR vote appropriate.
Overall Assessment
The 2026 Voyager Therapeutics annual meeting features four proposals: director elections, an advisory say-on-pay vote, auditor ratification, and a charter amendment to increase authorized shares. All three director nominees and all management proposals receive a FOR vote determination — the 3-year TSR underperformance trigger fires for all directors but is overridden by the 5-year mitigant showing Voyager outperformed peers over the longer window, and executive compensation is reasonable and well-structured for a biotech company at this stage.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing